C260-1390 Screening compound: N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{[1-(3,3-dimethyl-2-oxobutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]methyl}benzamide

C260-1390 Screening compound: N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{[1-(3,3-dimethyl-2-oxobutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]methyl}benzamide
C260-1390 Screening compound: N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{[1-(3,3-dimethyl-2-oxobutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]methyl}benzamide alternative view

Chemical Structure Depiction of ChemDiv screening compound C260-1390
N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{[1-(3,3-dimethyl-2-oxobutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]methyl}benzamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

C260-1390

Molecular Formula

C32H35N3O6 (C32 H35 N3 O6)

Compound Name

N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{[1-(3,3-dimethyl-2-oxobutyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl]methyl}benzamide

IUPAC name

N-[2-(34-dimethoxyphenyl)ethyl]-4-{[1-(33-dimethyl-2-oxobutyl)-24-dioxo-1234-tetrahydroquinazolin-3-yl]methyl}benzamide

SMILES

CC(C)(C)C(CN(c(cccc1)c1C(N1Cc(cc2)ccc2C(NCCc(cc2)cc(OC)c2OC)=O)=O)C1=O)=O

InChI

InChI=1S/C32H35N3O6/c1-32(2,3)28(36)20-34-25-9-7-6-8-24(25)30(38)35(31(34)39)19-22-10-13-23(14-11-22)29(37)33-17-16-21-12-15-26(40-4)27(18-21)41-5/h6-15,18H,16-17,19-20H2,1-5H3,(H,33,37)

InChI Key

SHEGDOGJLNETCR-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD14737838

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

557.65

Hydrogen Bond Acceptors Count

10.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

12.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

3.582

Distribution Coefficient, logD

3.582

Water Solubility, LogSw

-3.86

Polar Surface Area

84.301

Acid Dissociation Constant (pKa)

12.97

Base Dissociation Constant (pKb)

-2.97

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

31.30

C260-1390 in Drug Discovery

Included in Screening Libraries

3D-Biodiversity Library (27607 compounds)

Antiviral Annotated Library (21441 compounds)

Lipid Metabolism Library (9174 compounds)

ChemoGenomic Annotated Library for Phenotypic Screening (89798 compounds)

MCE-18 Trends in Medicinal Chemistry (51288 compounds)

Protein Tyrosine Phosphatase Non-receptor Type (PTPN) Targeted Library (32556 compounds)

Target Identification, Phenotypic Screening library (TIPS) (27612 compounds)

Included in 1.7M Stock Database

Structure:
  • 3D
Therapeutical areas:
  • Cardiovascular
  • Metabolic
  • Cancer
  • Nervous system
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Endocrine
Targets:
  • Phosphatases

References: we are preparing a list of scientific research reports with C260-1390 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound C260-1390?
Check Price and Availability of C260-1390, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of C260-1390 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for C260-1390
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for C260-1390
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of C260-1390 available by request